The headline EPS miss is mostly accounting noise, not operating deterioration. Reported second-quarter loss was $0.80 per share versus a published consensus of roughly $0.21 loss, but the gap was driven primarily by a $48.7 million non-cash increase in warrant-liability fair value (Financial Results). Core operating expenses were $18.4 million, up from $12.6 million a year earlier, reflecting the commercial and manufacturing buildout rather than a new clinical setback.
| Metric | Q2 2026 | Q2 2025 / expectation | Read |
|---|---|---|---|
| Operating expenses | $18.4 million | $12.6 million | Higher investment in launch readiness (Consolidated Statements of Loss) |
| Research and development | $3.8 million | $6.7 million | Lower clinical spending (Consolidated Statements of Loss) |
| General and administrative | $14.6 million | $5.9 million | More than doubled as commercial infrastructure expanded (Consolidated Statements of Loss) |
| Net loss | $74.8 million | $12.7 million | Distorted by $48.7 million non-cash warrant charge (Financial Results) |
| Basic and diluted loss per share | $0.80 | $0.37 / approximately $0.21 consensus loss | Reported miss, largely warrant-related (Consolidated Statements of Loss) |
| Cash, cash equivalents and marketable securities | $187.3 million | $36.4 million at December 31, 2025 | Liquidity materially strengthened (Consolidated Balance Sheets) |
The regulatory update is more confirmation than fresh bad news. Achieve says the June 20, 2026 Complete Response Letter was anticipated in April and cited manufacturing observations at the former facility plus unfinished labeling—not efficacy or clinical-safety deficiencies (Regulatory Update). That removes the worst-case interpretation, but it does not eliminate execution risk: the company still must complete the manufacturing transition and satisfy the FDA before approval.
Funding materially improves the path to resubmission and launch, with dilution attached. The private placement provides $180 million upfront and up to another $174 million through milestone-based warrants, while cash and marketable securities stood at $187.3 million at quarter-end (Capital Raise; Consolidated Balance Sheets). This is a meaningful financing de-risking, but the warrant and pre-funded warrant liability was already $183.4 million, and future warrant exercises could expand the share count (Consolidated Balance Sheets).
The key timeline is now clearer, but later than the market’s original approval setup. Management plans to resubmit the NDA with the new U.S. manufacturer in the fourth quarter of 2026 and now targets potential FDA approval in the first half of 2027, followed by launch (Regulatory Update). The filing adds progress—engineering production and testing qualification are complete, and long-term safety data showed no new signals in 475 participants (Scientific Data Advancement)—but the central value driver remains dependent on manufacturing remediation and FDA review. Net versus expectations, this is a better-funded and more execution-ready company, not a newly accelerated regulatory story.
Read the original 8-K on SEC EDGAR ↗